<DOC>
	<DOCNO>NCT00385411</DOCNO>
	<brief_summary>Main objective : Therapeutic follow-up study Evaluate clinical biological safety valproate administer microgranules , standard prescription condition , therapeutic follow-up individual dosage adjustment , use valproate plasma concentration antiepileptic comedication well biological assay . Secondary objective : Ancillary population kinetics study - Estimate pharmacokinetic parameter valproate administer microgranules standard therapeutic condition within population study , therapeutic follow-up data . - Evaluate influence individual characteristic pharmacokinetic parameter . - Describe relationship plasma concentration adverse event valproate main anti-epileptic comedications .</brief_summary>
	<brief_title>Study Valproate Young Patients Suffering From Epilepsy</brief_title>
	<detailed_description />
	<mesh_term>Epilepsy</mesh_term>
	<mesh_term>Valproic Acid</mesh_term>
	<criteria>Children age 6 month 15 year . Suffering type epilepsy . Receiving time inclusion valproate form MicropakineÂ® SR 20 30 mg/kg/d oral route , 2 daily administration two antiepileptic drug ( antiepileptic benzodiazepine treatment take daily demand 2 time weekly , must consider antiepileptic treatment ) . Followed hospital paediatrician neuropaediatricians . For consent sign parent holder parental authority possible child him/herself . For parent legal guardian language cultural obstacle understand study . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>6 Months</minimum_age>
	<maximum_age>15 Years</maximum_age>
	<verification_date>October 2009</verification_date>
</DOC>